Compare Invesco Preferred ETF (PGX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Preferred ETF vs ResMed Inc. — how do they compare? Invesco Preferred ETF trades at $10.01 (market cap $3.60B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 8.9× Invesco Preferred ETF's market cap, and ResMed Inc. pays a 1.16% dividend while Invesco Preferred ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Preferred ETF for 95 Days and ResMed Inc. for 51 Days on average.
| PGX | RMD | |
|---|---|---|
Market Cap | $3.60B | $31.89B |
Volume | 5,986,026 | 618,314 |
52-Week High | $11.61 | $277.88 |
52-Week Low | $9.97 | $182.82 |
Typical Hold Time | 95 Days | 51 Days |
Sector | — | Health |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PGX trades at $10.03 with a modest 0.6% daily gain, though technical indicators show a bearish trend with moving averages and ADX signaling selling pressure. The stock faces fundamental data gaps with key valuation and profitability metrics unavailable. Recent corporate actions include scheduled dividend payments of $0.06 per share in July and September 2026, providing income potential for shareholders.
The outlook remains cautious due to incomplete financial data and bearish technical signals. Investment opportunity exists through dividend income, but risks include limited fundamental visibility and technical weakness. Investors require updated SEC filings and analyst coverage to assess true valuation and growth prospects.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
